Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
You may also be interested in...
No Victory For Victoza: FDA Panel Splits On Whether Cancer Signal Should Block Approval
Liraglutide’s cardiovascular safety profile gets support from a majority of an FDA advisory committee, but a preclinical thyroid cancer risk results in a tied vote on the approvability of Novo Nordisk’s type 2 diabetes drug.
Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis
Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.
Amylin Will Add Pancreatitis Cautions To Byetta Label
FDA issues Medwatch alert warning health care professionals of 30 cases of acute pancreatitis in patients taking the type 2 diabetes drug